Sun Pharma Q2 net falls 46.5 pct on Protonix provision

MUMBAI Thu Nov 8, 2012 2:57pm IST

A pharmacists sorts free medication provided by the government, which will be given to patients, at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012. REUTERS/Babu/Files

A pharmacists sorts free medication provided by the government, which will be given to patients, at Rajiv Gandhi Government General Hospital (RGGGH) in Chennai July 12, 2012.

Credit: Reuters/Babu/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - Sun Pharmaceutical Industries (SUN.NS) reported a 46.5 percent drop in quarterly net profit after it set aside 5.84 billion rupees towards a possible compensation in a patent dispute case related to drug Protonix.

The Mumbai-based drugmaker said consolidated net profit fell to 3.2 billion rupees during fiscal second quarter ended September from 5.98 billion rupees a year earlier. Net sales rose 40.2 percent to 26.57 billion rupees.

Analysts had estimated the net profit at 7.68 billion rupees, according to Thomson Reuters I/B/E/S. (Reporting by Kaustubh Kulkarni; Editing by Jijo Jacob)

FILED UNDER:

Reuters Showcase

Trading Fees

Trading Fees

BSE slashes fees in FX derivatives battle with NSE  Full Article 

SpiceJet Turnaround

SpiceJet Turnaround

SpiceJet board approves up to $243 mln share sale plan  Full Article 

Currency Market

Currency Market

RBI urges companies to hedge FX exposure  Full Article 

Uber's Woes

Uber's Woes

Uber, other taxi-hailing apps hit new roadblock in Delhi.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage